Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients.

AIDS

aEmory University School of Medicine, Department of Medicine, Division of Infectious Diseases bCenter for AIDS Research, Emory University School of Medicine, Department of Pediatrics, Atlanta, Georgia cUniversity of Alabama-Birmingham School of Medicine, Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, Birmingham, Alabama dEmory University, Rollins School of Public Health, Department of Global Health, Atlanta eAtlanta VA Medical Center, Decatur, Georgia, USA.

Published: June 2015

Intracellular nucleoside reverse transcriptase inhibitor (NRTI) concentrations are associated with plasma HIV-1 response. Coadministration of protease inhibitors with NRTIs can affect intracellular concentrations due to protease inhibitor inhibition of efflux transporters. Tenofovir-diphosphate (TFV-DP) concentrations within peripheral blood mononuclear cells were compared among individuals receiving either atazanavir or darunavir-based regimens. There was a trend towards higher TFV-DP concentrations among women and among participants receiving atazanavir. TFV-DP intracellular concentrations were positively associated with undetectable plasma HIV-1 RNA.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490037PMC
http://dx.doi.org/10.1097/QAD.0000000000000659DOI Listing

Publication Analysis

Top Keywords

protease inhibitors
8
plasma hiv-1
8
intracellular concentrations
8
tfv-dp concentrations
8
receiving atazanavir
8
concentrations
5
impact protease
4
intracellular
4
inhibitors intracellular
4
intracellular concentration
4

Similar Publications

Dengue is one of the most prevalent viruses transmitted by the Aedes aegypti mosquitoes. Currently, no specific medication is available to treat dengue diseases. The NS2B-NS3 protease is vital during post-translational processing, which is a key target in this study.

View Article and Find Full Text PDF

Molecular Symphony of Mitophagy: Ubiquitin-Specific Protease-30 as a Maestro for Precision Management of Neurodegenerative Diseases.

CNS Neurosci Ther

January 2025

Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, USA.

Introduction: Mitochondrial dysfunction stands as a pivotal feature in neurodegenerative disorders, spurring the quest for targeted therapeutic interventions. This review examines Ubiquitin-Specific Protease 30 (USP30) as a master regulator of mitophagy with therapeutic promise in Alzheimer's disease (AD) and Parkinson's disease (PD). USP30's orchestration of mitophagy pathways, encompassing PINK1-dependent and PINK1-independent mechanisms, forms the crux of this exploration.

View Article and Find Full Text PDF

Background: The risk of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD) is estimated to be far greater than that in the general population. Adropin regulates endothelial function and may play a role in the pathogenesis of CVD. Angiotensin-converting enzyme inhibitor (ACEI) treatment was reported to have a protective effect on both renal and cardiovascular function.

View Article and Find Full Text PDF

The SERPINB4 gene mutation identified in twin patients with Crohn's disease impaires the intestinal epithelial cell functions.

Sci Rep

January 2025

Department of Gastroenterology, The National Key Clinical Specialty, Clinical Research Center for Gut Microbiota and Digestive Diseases of Fujian Province, Key Laboratory for Intestinal Microbiome and Human Health of Xiamen, Zhongshan Hospital of Xiamen University, Xiamen, 361004, China.

Crohn's disease (CD) is a chronic inflammatory autoimmune disease of unknown etiology. To identify new targets related to the initiation of CD, we screened a pair of twins with CD, which is a rare phenomenon in the Chinese population, for genetic susceptibility factors. Whole-exome sequencing (WES) of these patients revealed a mutation in their SERPINB4 gene.

View Article and Find Full Text PDF

Identification of potent TMPRSS4 inhibitors through structural modeling and molecular dynamics simulations.

Sci Rep

January 2025

Laboratory of Molecular Chemistry, Department of Chemistry, Faculty of Sciences Semlalia, Cadi Ayyad University, BP 2390, 40000, Marrakech, Morocco.

TMPRSS4, a transmembrane serine protease type II, is associated with various pathological illnesses. It has been found to activate SARS-CoV-2, enhance viral infection of human small-intestinal enterocytes and is overexpressed in different types of cancers. Therefore, this study aims to disover potential TMPRSS4 inhibitors that have better binding affinity than the approved inhibitors: 2-hydroxydiarylamide and tyroserleutide.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!